Posted by Michael Wonder on 08 Aug 2022
Pear Therapeutics and SelectHealth announce coverage to provide access to FDA authorised prescription digital therapeutic for the treatment of opioid use disorder
8 August 2022 - SelectHealth teams with Pear to provide its members with covered access to Pear’s innovative prescription digital therapeutic, reSET-O, for the treatment of opioid use disorder as adjunct to outpatient treatment that includes transmucosal buprenorphine medication assisted treatment.
Pear Therapeutics and SelectHealth, a Utah based not for profit health plan and wholly owned subsidiary of Intermountain Healthcare, announced today that reSET-O, the only FDA authorised PDT to treat opioid use disorder, has been added as a covered benefit for SelectHealth’s members.
